Durability of treatment response in patients with moderate to severe psoriasis following withdrawal from or a dose reduction in adalimumab therapy

被引：0
|
作者：
Blum, R
Lebwohl, M
Gottlieb, A
Chen, D
机构：
[1] Mt Sinai Sch Med, New York, NY USA
[2] Univ Med & Dent New Jersey, New Brunswick, NJ USA
[3] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2005年 / 52卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：P180 / P180
页数：1
相关论文
共 50 条
  • [31] Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis
    Ovejero-Benito, Maria C.
    Prieto-Perez, Rocio
    Llamas-Velasco, Mar
    Munoz-Aceituno, Ester
    Reolid, Alejandra
    Saiz-Rodriguez, Miriam
    Belmonte, Carmen
    Roman, Manuel
    Ochoa, Dolores
    Talegon, Maria
    Cabaleiro, Teresa
    Dauden, Esteban
    Abad-Santos, Francisco
    PHARMACOGENOMICS, 2018, 19 (01) : 7 - 16
  • [32] Adalimumab dose reduction in psoriasis: Results in a series of 12 patients
    Rodrigo-Nicolas, Beatriz
    Gimeno-Carpio, Enrique
    Quecedo-Estebanez, Esther
    Velasco-Pastor, Manuel
    Barrado-Solis, Nerea
    Moles-Poveda, Paula
    Pont-Sanjuan, Virginia
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB164 - AB164
  • [33] Dermatologic quality of life in patients with moderate to severe plaque psoriasis receiving 48 weeks of adalimumab therapy
    Wallace, K
    Gordon, K
    Langley, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P180 - P180
  • [34] Predicting PASI90 response among adalimumab-treated patients with moderate to severe psoriasis
    Ryan, Caitriona
    Sundaram, Murali
    Yang, Min
    Goyal, Ravi
    Zhou, Zhou
    Signorovitch, James
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB263 - AB263
  • [35] Treatment changes in patients with moderate to severe psoriasis
    Anderson, Kathryn
    Feldman, Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB256 - AB256
  • [36] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, Caitriona
    Crowley, Jeffrey
    Valdecantos, Wendell
    Wu, Tianshuang
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
  • [37] Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice
    Armesto, Susana
    Coto-Segura, Pablo
    Mayorga, Jesus
    Illaro, Aitziber
    Santos-Juanes, Jorge
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (01) : 49 - 53
  • [38] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, C.
    Crowley, J.
    Valdecantos, W.
    Wu, T.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 21
  • [39] Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
    Kim, Dong Hyun
    Son, Sang Wook
    Jeong, Ki-Heon
    Ahn, Jiyoung
    Lee, Eun-So
    Kim, Il-Hwan
    Ha Lee, Un
    Park, Hai-Jin
    Ko, Joo Yeon
    Kim, Byung-Soo
    Kim, Jin Ju
    Rashid, Javed
    Kim, Kwang Joong
    ANNALS OF DERMATOLOGY, 2023, 35 (02) : 107 - 115
  • [40] Role of topical therapy in the treatment of moderate to severe psoriasis
    Feldman, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB224 - AB224
12345